Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, preventatives, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

506

$million

Invested

113

innovative

Projects

14

different

Countries

12

human clinical

TRIALS

3

available

DIAGNOSTICS

10

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2024

Annual Report

Accelerating Innovation to Protect Lives from Bacterial Infections

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
Wellcome
NIAID
Federal Ministry of Research, Technology and Space
UK Government
Gates Foundation
The Public Health Agency of Canada
Novo Nordisk Foundation

Events

Events

07.27.25

 

Association for Diagnostics & Laboratory Medicine 2025

10.01.25

 

Global AMR Innovators Conference (GAMRIC)

10.12.25

 

World Health Summit 2025

CARB-X News

  • 04.30.2025  |  CARB-X releases 2024 Annual Report celebrating a year of progress full release

  • 04.02.2025  |  CARB-X funds ArrePath to advance novel antibiotic to treat multidrug-resistant infections full release

  • 02.26.2025  |  CARB-X launches 2025 Funding Round targeting global infectious disease threats full release

See All News

In The News

  • 05.13.2025  |  Bridging global expertise with South Australia’s ingenuity to tackle antimicrobial resistance full story

  • 04.16.2025  |  Taking the Australian AMR story to ESCMID Global Congress in Vienna full story

  • 04.15.2025  |  Antimicrobial resistance: Q&A with CARB-X about the fight against AMR full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.

Subscribe

* indicates required